Opinion statement Pancreatic cancer is mainly diagnosed at an advanced, often metastatic
stage and still has a poor prognosis. Over the last decades, chemotherapy of metastatic …

Pancreatic cancer is the fourth leading cause of cancer-related death in the USA and
Europe; early symptoms and screenings are lacking, and it is usually diagnosed late with a …

Background Liposomal irinotecan (nal-IRI) plus 5-fluorouracil and leucovorin (5-FU/LV) is
approved for patients with metastatic pancreatic ductal adenocarcinoma (mPDAC) …

Background Biomarkers predicting treatment response may be used to stratify patients with
pancreatic ductal adenocarcinoma (PDAC) for available therapies. The aim of this study was …

Pancreatic ductal adenocarcinoma (PDAC) is one of the deadliest solid tumors with a high
mortality rate and poor survival rate. Depending on the tumor stage, PDAC is either treated …

Familiäres Pankreaskarzinom (S. e836): Hier wird erstmals definiert, welchen Angehörigen
von Patienten mit familiärem Pankreaskarzinom welche genetischen Untersuchungen zur …

Simple Summary Despite advancements in surgical oncology and chemoradiation
therapies, pancreatic cancer still has one of the lowest 5-year survival rates in the United …

Abstract Introduction 5-fluorouracil, folinic acid, irinotecan and oxaliplatin (FOLFIRINOX) is
promising in treating patients with pancreatic ductal adenocarcinoma. However, many …

In this study, we explored the predictive value of serum microRNA (miRNA) expression for
early tumor progression during FOLFIRINOX chemotherapy and its association with overall …

Background: Pancreatic adenocarcinoma is one of the cancers with the worst prognosis.
The current treatment paradigm based on combination chemotherapy has improved survival …